Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study
曲妥珠单抗和吡咯替尼联合达匹西利新辅助治疗HR阴性/HER2阳性乳腺癌的疗效和安全性:一项探索性、开放标签的II期研究
期刊:International Journal of Surgery
影响因子:10.1
doi:10.1097/JS9.0000000000003328
Xiao, Zhi; Chen, Feiyu; Liao, Liqiu; Luo, Shayang; Liu, Xuan; Liu, Xiangyan; Xu, Tao; Hu, Yu; Luo, Na; Wang, Wenlong; Cao, Jing; Wang, Kuansong; Zhou, Haiyan; Ding, Nianhua; Li, Yan; Huang, Juan; Wang, Shouman